145 related articles for article (PubMed ID: 10910918)
21. Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV.
Boutboul F; Puthier D; Appay V; Pellé O; Ait-Mohand H; Combadière B; Carcelain G; Katlama C; Rowland-Jones SL; Debré P; Nguyen C; Autran B
AIDS; 2005 Nov; 19(17):1981-6. PubMed ID: 16260904
[TBL] [Abstract][Full Text] [Related]
22. Expansion of a CD28-intermediate subset among CD8 T cells in patients with infectious mononucleosis.
Uda H; Mima T; Yamaguchi N; Katada Y; Fukuda M; Fujii N; Nakamura K; Saiki O
J Virol; 2002 Jul; 76(13):6602-8. PubMed ID: 12050373
[TBL] [Abstract][Full Text] [Related]
23. IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells.
Alves NL; Arosa FA; van Lier RA
J Immunol; 2005 Jul; 175(2):755-62. PubMed ID: 16002671
[TBL] [Abstract][Full Text] [Related]
24. Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression.
Meng Y; Harlin H; O'Keefe JP; Gajewski TF
J Immunol; 2006 Aug; 177(3):1981-7. PubMed ID: 16849512
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies.
Li Q; Yu B; Grover AC; Zeng X; Chang AE
J Immunother; 2002; 25(4):304-13. PubMed ID: 12142553
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of B7-1 and B7-2 on the costimulation of mouse nonspecific cytotoxic T lymphocyte development in response to anti-CD3 antibody.
Makrigiannis AP; Musgrave BL; Hoskin DW
J Leukoc Biol; 1999 Nov; 66(5):792-802. PubMed ID: 10577511
[TBL] [Abstract][Full Text] [Related]
27. Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells.
Hilchey SP; De A; Rimsza LM; Bankert RB; Bernstein SH
J Immunol; 2007 Apr; 178(7):4051-61. PubMed ID: 17371959
[TBL] [Abstract][Full Text] [Related]
28. CD8+CD28- T cells: certainties and uncertainties of a prevalent human T-cell subset.
Arosa FA
Immunol Cell Biol; 2002 Feb; 80(1):1-13. PubMed ID: 11869357
[TBL] [Abstract][Full Text] [Related]
29. Detailed immunophenotype of CD8+ memory cytotoxic T-lymphocytes (CTL) against HIV-1 with respect to expression of CD45RA/RO, CD62L and CD28 antigens.
Giorgi JV; Hausner MA; Hultin LE
Immunol Lett; 1999 Mar; 66(1-3):105-10. PubMed ID: 10203041
[TBL] [Abstract][Full Text] [Related]
30. Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions.
Patel SD; Ge Y; Moskalenko M; McArthur JG
J Immunother; 2000; 23(6):661-8. PubMed ID: 11186154
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene.
Yu K; Hu Y; Tan Y; Shen Z; Jiang S; Qian H; Liang B; Shan D
Leuk Lymphoma; 2008 Jul; 49(7):1368-73. PubMed ID: 18452062
[TBL] [Abstract][Full Text] [Related]
32. Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells.
Zheng Y; Yu K; Du J; Jiang L; Zhang S; Han Y; Yu P; Tan Y
J Exp Clin Cancer Res; 2010 Sep; 29(1):121. PubMed ID: 20815894
[TBL] [Abstract][Full Text] [Related]
33. T helper-independent activation of human CD8+ cells: the role of CD28 costimulation.
Van Gool SW; Zhang Y; Kasran A; de Boer M; Ceuppens JL
Scand J Immunol; 1996 Jul; 44(1):21-9. PubMed ID: 8693288
[TBL] [Abstract][Full Text] [Related]
34. An additional CD28 costimulatory signal enhances proliferation and cytotoxicity of murine T cell-derived CIK cell.
Timalsena S; Pluangnooch P; Wongkajornsilp A; Soontrapa K
Asian Pac J Allergy Immunol; 2017 Jun; 35(2):67-74. PubMed ID: 27543727
[TBL] [Abstract][Full Text] [Related]
35. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
36. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial.
Lum LG; LeFever AV; Treisman JS; Garlie NK; Hanson JP
J Immunother; 2001; 24(5):408-19. PubMed ID: 11696696
[TBL] [Abstract][Full Text] [Related]
37. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
38. Engagement of CD28 modulates CXC chemokine receptor 4 surface expression in both resting and CD3-stimulated CD4+ T cells.
Secchiero P; Zella D; Curreli S; Mirandola P; Capitani S; Gallo RC; Zauli G
J Immunol; 2000 Apr; 164(8):4018-24. PubMed ID: 10754293
[TBL] [Abstract][Full Text] [Related]
39. BY55/CD160 cannot be considered a cytotoxic marker in cytomegalovirus-specific human CD8(+) T cells.
Merino J; Ramírez N; Moreno C; Toledo E; Fernández M; Sánchez-Ibarrola A
Clin Exp Immunol; 2007 Jul; 149(1):87-96. PubMed ID: 17425655
[TBL] [Abstract][Full Text] [Related]
40. Peripheral human CD8(+)CD28(+)T lymphocytes give rise to CD28(-)progeny, but IL-4 prevents loss of CD28 expression.
Labalette M; Leteurtre E; Thumerelle C; Grutzmacher C; Tourvieille B; Dessaint JP
Int Immunol; 1999 Aug; 11(8):1327-36. PubMed ID: 10421790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
